On the website of the FEMEBA Foundation (Medical Federation of the Province of Buenos Aires), you will find the translated summaries of the following selected works referring to the use of medications:
Efficacy of BIV1-CovIran Inactivated Whole Viral Particle Vaccine for SARS-CoV-2 | BMJ, September 21, 2023.
In a clinical trial conducted in Iran during the prevalence of the delta variant of the virus, two doses of the BIV1-CovIran vaccine separated by four weeks had an efficacy of 50.2% (44.7% to 55.0%) against the symptomatic covid-19, 70.5% (63.7% to 76.1%) against severe disease and 83.1% (61.2% to 93.5%) against critical cases. There were no serious adverse events related to the injections.
Click here.
Inhaled corticosteroids in mild to moderate Covid: final report of the ACTIV-6 study | N Engl J Med, September 21, 2023.
Treatment with inhaled fluticasone furoate for 14 days did not result in a shorter recovery time than placebo among outpatients with mild to moderate Covid-19 in the United States.
Click here.
Outpatient Covid-19 treatment: an updated version of the American College of Physicians guideline | Ann Intern Med, September 19, 2023.
These revised guidelines suggest using molnupiravir or the nirmatrelvir-ritonavir combination in outpatients with confirmed mild to moderate COVID-19 who are at high risk of progressing to severe disease and are within 5 days of symptom onset. Other sources question these recommendations and even the European Medicines Agency did not accept the registration of molnupiravir.
Click here.
STOP COVID 2 Study: Fluvoxamine Versus Placebo for Outpatients With Symptomatic COVID-19 | Open Forum Infect Dis, August 8, 2023.
This fully remote randomized controlled trial did not find fluvoxamine to be effective in preventing clinical deterioration in unvaccinated outpatients with symptomatic COVID-19. It was stopped early and was underpowered due to low rates of primary outcomes.
Click here.
2023-09-25 18:46:11
#COVID19 #Pharmacotherapy #FEMEBA #Foundation #website #September #CIME #CIME
